Section 9.1
Diuretic Therapies
Explain how thiazide, loop, and potassium-sparing diuretics change nephron transport, then choose monitoring priorities from the fluid and electrolyte consequences.
Learn
Idea 1 / 4
Diuresis follows sodium handling
A diuretic increases urine formation by reducing renal sodium reabsorption. Water follows the sodium that remains in the tubular fluid, so circulating volume may fall. The nephron is the kidney’s working unit: its tubule reclaims useful substances and leaves a changing mixture of water and electrolytes to become urine. The class, dose, kidney function, and patient’s starting volume determine how large that change is.
An ankle swollen from heart failure may improve when excess sodium and water are removed, but dizziness, thirst, falling blood pressure, or a rising creatinine can signal that removal has become excessive.
Read all essential notes
Diuresis follows sodium handling
A diuretic increases urine formation by reducing renal sodium reabsorption. Water follows the sodium that remains in the tubular fluid, so circulating volume may fall. The nephron is the kidney’s working unit: its tubule reclaims useful substances and leaves a changing mixture of water and electrolytes to become urine. The class, dose, kidney function, and patient’s starting volume determine how large that change is.
An ankle swollen from heart failure may improve when excess sodium and water are removed, but dizziness, thirst, falling blood pressure, or a rising creatinine can signal that removal has become excessive.
The nephron site predicts intensity
Thiazides reduce sodium chloride reabsorption in the distal convoluted tubule and are usually moderate diuretics. Loop diuretics inhibit the Na-K-2Cl transporter in the thick ascending limb, a segment that normally helps build the medullary concentration gradient; they therefore produce a larger, faster diuresis. Potassium-sparing drugs act later. Amiloride blocks epithelial sodium channels, while spironolactone opposes aldosterone’s signal, so both conserve potassium but are less powerful as stand-alone diuretics.
The same “water pill” label hides different decisions: brisk edema may need a loop, long-term blood-pressure control may use a thiazide, and aldosterone-driven fluid retention may make spironolactone useful.
Potassium is the key trade-off
Thiazides and loops commonly increase potassium loss because more sodium reaches potassium-secreting segments. Low potassium can cause weakness and make some arrhythmias more dangerous. Potassium-sparing agents reduce potassium loss, but that benefit can become hyperkalemia when kidney excretion is poor or when potassium supplements, ACE inhibitors, angiotensin-receptor blockers, or other potassium-raising medicines are present. The direction of the electrolyte change must be linked to the class rather than memorized as a universal rule.
A patient taking spironolactone who also uses a potassium-based salt substitute needs potassium and renal-function review; automatically adding potassium would ignore the mechanism.
Measure response and harm together
Useful follow-up combines the treatment target with safety data: symptoms and edema, weight trend, blood pressure, urine output when relevant, serum electrolytes, and renal markers. Furosemide labeling warns about dehydration, electrolyte abnormalities, worsening renal function, and ototoxicity with rapid or high-dose parenteral treatment. Spironolactone labeling calls for potassium and renal monitoring because hyperkalemia risk rises with impaired renal function or other potassium-raising treatments. A single better number never cancels the rest of the assessment.
A falling weight may mean effective decongestion, but if it comes with orthostasis, cramps, oliguria, or rising creatinine, the plan needs clinical reassessment rather than an automatic dose increase.
Common misconception: “More urine always means better treatment.” Urine volume is an effect, not the goal by itself; excessive diuresis can cause dehydration, electrolyte injury, hypotension, or renal deterioration.
Explore
Follow the mechanism. Select a step to explain what changes and why. This is a schematic, not a physiological simulation.
Step 1 / 4
Sodium remains in tubular fluid
The chosen diuretic reduces sodium reabsorption at its nephron target.
Go deeper: worked example
A person with heart failure starts furosemide and loses weight over three days. They now report thirst and dizziness when standing; potassium is low and creatinine has risen. What does the team need to connect before changing the plan?
- First identify the intended effect: furosemide increases sodium and water excretion, so less edema and weight may show decongestion.
- Then identify the competing signal: thirst, orthostasis, and rising creatinine suggest intravascular depletion or worsening renal perfusion, not simply “the drug is working.”
- Low potassium adds a separate hazard because loop-related electrolyte loss can increase weakness and arrhythmia risk, especially with other cardiac medicines.
- The next step is a clinician-led review of volume status, dose and timing, renal function, electrolytes, intake, and interacting drugs; it is not an automatic increase or abrupt self-stop.
Effective diuresis is a balance: the target improves while circulating volume, electrolytes, renal function, and symptoms remain acceptable.
Explain it yourself
Why can spironolactone conserve potassium yet still require closer monitoring in kidney disease?
Reveal explanation
Its aldosterone-blocking effect reduces potassium secretion, and impaired kidneys have less reserve to remove potassium. The combination can make hyperkalemia more likely, especially with potassium supplements or other potassium-raising drugs.
Create and evaluate
Create a one-page monitoring map for a new diuretic: link the nephron site, expected fluid effect, electrolyte direction, patient observations, laboratory checks, and escalation triggers.
Formative activity: compare your reasoning with the rubric. This response is not automatically graded and does not award mastery. It remains only on this page and is cleared when you leave.
Compare with the rubric and example
- Mechanism: names the nephron target and connects sodium handling to water movement.
- Trade-off: predicts the relevant potassium or volume risk for the class.
- Plan: includes symptoms, blood pressure or weight, renal function, electrolytes, interactions, and a clinician review trigger.
For furosemide, expect brisk sodium and water loss with possible hypokalemia and volume depletion; follow weight and edema alongside blood pressure, orthostasis, intake, renal markers and electrolytes, and review ototoxic-risk combinations or rapid parenteral use. For spironolactone, add potassium-focused and renal monitoring because potassium may rise.
Sources and review status
Educational draft. Medical and French-language expert review pending. External sources require an internet connection; essential explanations are included above.
- Clinical Pharmacology Made Incredibly Easy!, 3rd ed., Chapter 9
PDF index page 223; printed pp. 223–230 (diuretics and monitoring)
- DailyMed: Furosemide injection, official prescribing information
Warnings and Precautions 5.1–5.3: fluid/electrolyte abnormalities, renal function, ototoxicity
- DailyMed: Spironolactone tablets, official prescribing information
Sections 4–5.2: hyperkalemia, renal impairment, monitoring
Check my understanding
Mastery Question Gate
Answer all questions correctly to unlock the next lesson. Retakes vary the selection when enough questions are available; some questions may repeat.
1. What unique organ toxicity is associated with rapid IV administration of high-dose furosemide?